Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers

BACKGROUND: Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35–40% of patients with HR+/HER2– breast cancer. Preclinically, cancer cells harboring double or multiple PIK3CA mutations (mut) elicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutchinson, Katherine E., Chen, Jessica W., Savage, Heidi M., Stout, Thomas J., Schimmoller, Frauke, Cortés, Javier, Dent, Susan, Harbeck, Nadia, Jacot, William, Krop, Ian, Trabucco, Sally E., Sivakumar, Smruthy, Sokol, Ethan S., Wilson, Timothy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131374/
https://www.ncbi.nlm.nih.gov/pubmed/37101291
http://dx.doi.org/10.1186/s13073-023-01181-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131374/
https://www.ncbi.nlm.nih.gov/pubmed/37101291
http://dx.doi.org/10.1186/s13073-023-01181-8

Ejemplares similares